The feasibility of using an NPM inhibitor as a therapeutic tool is confirmed by the fact that two phases, two clinical trials, adopting two different NPM inhibitors for anti-cancer therapy in humans, showed to be safe, non-toxic, and well-tolerated and have been completed successfully [reviewed in (41)]. The gene discussed is NPM1; the disease is cancer.